KDR and hepatocellular carcinoma: Another representative drug, sorafenib,215 is a typical multitarget drug targeting TKs such as VEGFR2 and PDGFR‐β, as well as the serine/threonine kinase Raf‐1,216 and can be used for the treatment of hepatocellular carcinoma (HCC) and renal cell carcinoma (RCC).217, 218